EMPEROR-Preserved
2021
Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved EF
In 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.
Result
Efficacy: HF hospitalisation or CV deathHR 0.79 (95% CI 0.69-0.90) · P < 0.001
Below 1 favours empagliflozin, above 1 favours placebo.
- Absolute difference
- 3.3 points
- NNT
- 31
Absolute difference and NNT are derived from the event rates.
Also reported: Driven primarily by HF hosp.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Anker SD, et al. N Engl J Med. 2021;385(16):1451-1461.doi 10.1056/NEJMoa2107038
Discussion & critique
First unambiguous pharmacological win in HFpEF. Benefit attenuates at very high EF (> 65 %) in pooled analyses. No mortality reduction.